Work­ing to get its pain R&D strat­e­gy back on track, Acel­Rx steps clos­er to an FDA pitch

Acel­Rx has de­liv­ered an­oth­er pos­i­tive piece of the Phase III puz­zle for ARX-04, its un­der-the-tongue ap­pli­ca­tion of a 30 mcg dose of the pow­er­ful opi­oid sufen­tanil de­signed to de­liv­er a jolt of fast pain re­lief.

Ex­pand­ing on an im­prove­ment in pain scores al­ready record­ed for the first co­hort of 40 in­jured pa­tients who turned up at the ER and re­ceived a sin­gle dose of ARX-04, the Red­wood City, CA-based biotech says that it record­ed a slight­ly bet­ter out­come for a small group of 36 more pa­tients who were green-light­ed for mul­ti­ple ap­pli­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER